



PATENT APPLICATION *HW*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Attorney Docket No.: 3364.25US01

Hinz

Confirmation No.: 8497

Application No.: 10/785,158

Examiner: Unknown

Filed: February 23, 2004

Group Art Unit: 1614

For: SEROTONIN AND CATECHOLAMINE SYSTEM SEGMENT OPTIMIZATION
TECHNOLOGY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. § 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached Form PTO-1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The listing of a reference herein is not an admission that the reference is prior art or that the reference is material to patentability.

This information is being filed before the mailing date of a first Office Action on the merits. No certification or fee is required. This application was filed after June 30, 2003; therefore, copies of cited U.S. patents and U.S. published applications are not included.

Respectfully submitted,

Brian L. Stender
Registration No. 56,836



Application No. 10/785,158

Customer No. 24113
Patterson, Thunte, Skaar & Christensen, P.A.
4800 IDS Center
80 South 8th Street
Minneapolis, Minnesota 55402-2100
Telephone: (612) 252-1548

Please grant any extension of time necessary for entry; charge any fee due to Deposit Account No. 16-0631.

CERTIFICATE OF MAILING


I hereby certify that this document is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

April 7, 2006

Date of Deposit



Brian L. Stender



Substitute for form 1449/PTO

SUPPLEMENTAL INFORMATION
DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/785,158

Filing Date February 23, 2004

First Named Inventor Martin C. Hinz

Art Unit 1614

Examiner Name Unknown

Sheet 1 of 5 Attorney Docket Number 3364.25US01

U.S. PATENT DOCUMENTS

EXAMINER INITIAL [*]	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number-Kind Code ² (if known)		
		US-2001/0002269	05-31-2001	Zhao
		US-2001/0008641	07-19-2001	Krotzer
		US-2001/0008884	07-19-2001	Worsley
		US-2001/0020007	09-06-2001	Wiss
		US-2002/0147206	10-10-2002	Howard, Jr.
		US-2002/0187958	12-12-2002	Horrobin et al.
		US-2004/0071681	04-15-2004	Muller
		US-2004/0077556	04-22-2004	Chinery
		US-2004/0081678	04-29-2004	Cincotta
		US-2004/0116351	06-17-2004	Halevie-Goldman
		US-2004/0151771	08-05-2004	Gin et al.
		US-2004/0247669	12-09-2004	Gin et al.
		US-2005/0233014	10-20-2005	Lee et al.
		US-2005/0287226	12-29-2005	Sisco et al.
		US-3,097,947	07-16-1963	Kemmerer
		US-4,237,118	12-02-1980	Howard
		US-4,397,866	08-09-1983	Wurtman
		US-5,019,594	05-28-1991	Wurtman et al.
		US-5,480,657	01-02-1996	Allen
		US-5,795,895	08-18-1998	Anchors
		US-5,977,099	1-02-1999	Nickolson
		US-6,207,699	03-27-2001	Rothman
		US-6,660,777	12-09-2003	Hinz

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)			
		JP10067663A2	03-10-1998	Nickolson	

EXAMINER
SIGNATUREDATE
CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614
				Examiner Name	Unknown
Sheet	2	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		ABELL ET AL., "Placebo Controlled Double-Blind Trial of Fluvoxamine Maleate in the Obese" <u>Journal of Psychosomatic Research</u> , 30(2): 143-146 (1986).			
		ACN Annual Meeting, San Juan, Puerto Rico, Dec. 15, 2000, PRNewswire (Abstract).			
		AGUNDEZ ET AL., "Modulation of CyPIA2 enzyme activity by indoleamines: inhibition by serotonin and tryptamine", <u>Pharmacogenetics</u> , 8:251-258 (1998).			
		Anchors Book, "Safer Than Phen-Fen" Anchors (Ed.), page 82.			
		ANDREWS ET AL., "The Effects of 5-hydroxytryptophan and 5-hydroxytryptamine on Dopamine Synthesis and Release in Rat Brain Striatal Synaptosomes", <u>Journal of Neurochemistry</u> , 30:465-470 (1978).			
		AVARELLO, "Serotonin Syndrome: a reported case", <u>Neuro Sci.</u> 23:S55-S56 (2002).			
		BARTHOLOME ET AL., "L-dopa and 5-hydroxytryptophan Therapy in Phenlalanine-Hydroxylase Activity", <u>The Lancet</u> 2 (Nov. 22): 1042-1043 (1975).			
		BAUMANN ET AL., "Transport Mechanisms for the Antidepressant Citalopram in Brain Microvessel Endothelium", <u>Brain Res.</u> 831(1-2); 229-36 (1999) (Abstract).			
		BOUCHARD ET AL., "Citalopram and Viloxazine in the treatment of depression by means of slow drop infusion A double-linked Comparative Trial", <u>Journal of Affective Disorders</u> 46:51-58 (1997).			
		COPPEN ET AL. "Levodopa and L-tryptophan Therapy in Parkinsonism", <u>The Lancet</u> , March 25, 1972.			
		Drug Facts and Comparison 1999 Edition, Riley (ed).			
		DUNNER ET AL., "Affective Disorder: Studeis with Amine Precursors", <u>Am J. Psychiatry</u> 132(2): 180-183 (1975).			
		FAVA, "Weight Gain and Antidepressants", <u>J. Clin Psychiatry</u> , 61 (Suppl 11 (1-2):37-41 (2000)(Abstract).			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		FAVA ET AL., "Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment", <u>J. Clin. Psychiatry</u> , 61(11): 863-7 (2000) (Abstract).			
		FOGLIA ET AL., "Plasma levels of citalopram enantiomers and metabolites in elderly patients", <u>Psychopharmacol Bull</u> , 33(1):109-12 (1997) (Abstract).			
		GELENBERG ET AL., "Tyrosine for the treatment of depression", <u>Nutr. Health</u> , 3(3):163-73 (1984).			
		HARVEY ET AL., "Neuropharmacology of paradoxical weight gain with selective serotonin reuptake inhibitors", <u>Clin Neuropharmacol</u> , 23(2):90-7 (Mar-Apr 2000) Abstract.			
		HURLEY ET AL., "Pyrrolo [1,4] benzodiazepine Antibiotics. Biosynthesis of the Antitumor Antibiotic 11-Demethylmaymycin and its Biologically Inactive metabolite Oxotomaymycin to Streptomyces achromogene, <u>Biochemistry</u> , 15(17):3760-3769 (1976).			
		KRAMARCY ET AL., "Effects of Drug-Induced Changes in Brain Monoamines on Aggression and Motor Behavior in Mice", <u>European Journal of Pharmacology</u> , 99:141-151 (1984).			
		LEINONEN ET AL., "Efficacy and tolerability of mirtazapine versus citalopram: a double-blind randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group", <u>Int. Clin Psychopharmacol.</u> , 14(6):329-37 (1999) (Abstract).			
		LI KAM WA ET AL., "Renal metabolism and effects of the glutamyl derivatives of L-dopa and 5-hydroxytryptophan in man", <u>Clinical Science</u> , 91:177-185 (1996).			
		LINDSTROM, "Aromatic-L-Amino-Acid Decarboxylase Activity in Mouse Pancreatic Islets", <u>Biochimica et Biophysica Acta</u> , 884:276-281 (1986).			
		LINDSTROM, ET AL., "Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan", <u>Molecular and Cellular Endocrinology</u> , 48:121-126 (1986).			
EXAMINER SIGNATURE				DATE CONSIDERED	
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p>					
<i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i>					

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		MALONE ET AL., "Treatment (Rx) of 76 Pateitns with Primary Fibromyalgia (1° FM) with Combined Dopaminergic and Serotonergic Drugs", Arthritis & Rheumatism, 39:S92 (1992) (Abstract).			
		MAREK ET AL., "A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action", <u>Psychopharmacology</u> 109:2-11 (1992).			
		MATHIAU ET AL, "Absence of Serotonergic Innervation from Raphe Nuclie in Rat Cerebral Blood Vessels – II. Lack of Tryptophan Hydroxylase Activity <i>In Vitro</i> " <u>Neuroscience</u> , 52(3): 657-665 (1993).			
		The Medical Letter, "Fluoxetine (prozac) and Other Drugs for Treatment of Obesity" Abranowics et al (Ed.)			
		The Merck Index, Budavari et al., (Ed.)			
		MEYERS, "Use of Neurotransmitter Precursors for Treatment of Depression", <u>Alternative Medicine Review</u> , 5(1):64-71 (2000).			
		MOON, "The Effects of Psychomotor Performance of Fluvoxamine Versus Miamserin in Depressed Patients in General Practice", <u>BJCP</u> , 45(4): 259-262 (1991).			
		NIEDENS ET AL, "First fungal aromatic L-amino acid decarboxylase from a paclitaxel-producing <i>Penicillium raistrickii</i> ", <u>Mycologia</u> , 91(4):61-26 (1999) (Abstract).			
		RABEY ET AL., "L-tryptophan Administration in L-Dopa-Induced Hallucinations in Elderly Parkinsonian Patients" <u>Gerontology</u> , 23:438-444 (1977).			
		SAWAKI ET AL., "Some correlations between Procaine-Induces Convulsions and Monamines in the Spinal Cord of Rats", <u>Japan, J. Pharmacol</u> , 51:369-376 (1989).			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					

Substitute for form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/785,158
				Filing Date	February 23, 2004
				First Named Inventor	Martin C. Hinz
				Art Unit	1614
				Examiner Name	Unknown
Sheet	4	of	5	Attorney Docket Number	3364.25US01
NON PATENT LITERATURE DOCUMENTS					
EXAMINER INITIAL*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published			T ²
		SCHLOSBERG ET AL., "Effects of L-Dopa and L-5-Hydroxytryptophan on Locomotor Activity of the Rat after Selective or combined destruction of Central Catecholamine and Serotonin Neurons", <u>The Journal of Pharmacology and Experimental Therapeutics</u> , 211(2):296-304 (1979).			
		SHINTAKU ET AL., "Diagnosis and treatment of 6-pyruvoyl-tetrahydropterin synthase deficiency", <u>Brain & Development</u> , 22:S118-S121 (2000).			
		STERNBERG ET AL., "Development of Scleroderma-like Illness during Therapy with L-5-hydroxytryptophan and Carbidopa", <u>The New England Journal of Medicine</u> , 303(14):782-787 (1980).			
		TANAKA ET AL., "Hyperphenylalaninemia Due to Impaired Dihydrobiopterin Biosynthesis", <u>Eur. J. Pediatr</u> , 136:275-280 (1981).			
		THURMOND ET AL., "Effects of Dietary Tyrosine, Phenylalanine, and Tryptophan on Aggression in Mice", <u>Pharmacology Biochemistry & Behavior</u> , 6:475-478 (1977).			
		TRULSON ET AL., "Behavioral Effects of Serotonergic and Dopaminergic Drugs in Cats Following Chronic Amphetamine Administration", <u>European Journal of Pharmacology</u> , 99:313-324 (1984).			
		WEITBRECHT ET AL., "Der Einfluss von L-Tryptophan auf die L-Dopa-Resorption", <u>Dtsch Med Wochenschr</u> , 101(1): 20-22 (1976).			
		Neuroscience Litigation Pleadings			
		Dave Peterson Affidavit (April 11, 2005)			
EXAMINER SIGNATURE		DATE CONSIDERED			
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.</p> <p>This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.</p> <p style="text-align: center;"><i>If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.</i></p>					